Evaluation of the effects of increasing tamoxifen dose on the treatment process in breast cancer patients
Phase 2
- Conditions
- Breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT2015082323734N1
- Lead Sponsor
- Isfahan University of Medical Siences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Women were eligible if they were on tamoxifen 20 mg daily for at least 4 months; nonpregnant; had normal kidney, liver, and bone marrow function.
Patients were excluded if they had a concurrent medication therapy with medications known to
inhibit CYP2D6.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endoxifen. Timepoint: After using 20mg/day tamoxifen for at least 4 month, 4 month after intervention. Method of measurement: Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS).
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: Four months after intervention. Method of measurement: Questionnaires.